Amedisys, Inc. (NASDAQ:AMED) reached a new 52-week low on Tuesday . The company traded as low as $166.00 and last traded at $166.77, with a volume of 2352 shares. The stock had previously closed at $167.67.
A number of equities analysts have recently weighed in on AMED shares. Raymond James lowered their price target on Amedisys from $325.00 to $250.00 and set an “outperform” rating for the company in a report on Monday, August 9th. Credit Suisse Group lowered their price target on Amedisys from $330.00 to $250.00 and set an “outperform” rating for the company in a report on Wednesday, August 11th. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating and set a $273.00 price target for the company. in a report on Tuesday, June 15th. Bank of America cut Amedisys from a “buy” rating to a “neutral” rating and set a $220.00 price target for the company. in a report on Thursday, August 5th. Finally, Oppenheimer reiterated a “buy” rating and set a $265.00 price target on shares of Amedisys in a report on Friday. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $269.83.
The company has a 50 day moving average of $207.23 and a 200-day moving average of $243.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.87 and a current ratio of 0.87. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 22.51, a price-to-earnings-growth ratio of 2.69 and a beta of 0.51.
Amedisys announced that its board has initiated a share repurchase plan on Wednesday, August 4th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the health services provider to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
In other news, Director Bruce D. Perkins sold 11,511 shares of the firm’s stock in a transaction dated Wednesday, September 1st. The stock was sold at an average price of $183.00, for a total transaction of $2,106,513.00. Following the sale, the director now owns 29,380 shares of the company’s stock, valued at approximately $5,376,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Christopher Gerard sold 1,250 shares of the firm’s stock in a transaction dated Monday, August 2nd. The stock was sold at an average price of $261.24, for a total value of $326,550.00. Following the sale, the chief operating officer now directly owns 39,006 shares in the company, valued at approximately $10,189,927.44. The disclosure for this sale can be found here. 1.80% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Amedisys during the 2nd quarter worth about $72,000. Eubel Brady & Suttman Asset Management Inc. purchased a new position in Amedisys during the 2nd quarter worth approximately $26,000. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Amedisys by 55.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 169 shares of the health services provider’s stock worth $45,000 after buying an additional 60 shares during the last quarter. Van ECK Associates Corp purchased a new position in Amedisys during the 1st quarter worth approximately $48,000. Finally, First Horizon Advisors Inc. grew its stake in Amedisys by 38.0% during the 1st quarter. First Horizon Advisors Inc. now owns 247 shares of the health services provider’s stock worth $65,000 after buying an additional 68 shares during the last quarter. 87.35% of the stock is currently owned by institutional investors and hedge funds.
About Amedisys (NASDAQ:AMED)
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.